STOCK TITAN

89bio, Inc. - $ETNB STOCK NEWS

Welcome to our dedicated page for 89bio news (Ticker: $ETNB), a resource for investors and traders seeking the latest updates and insights on 89bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 89bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 89bio's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.18%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences clinical trial
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.73%
Tags
89bio, Inc.

Nasdaq:ETNB

ETNB Rankings

ETNB Stock Data

877.97M
69.50M
0.86%
106.21%
12.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO

About ETNB

89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.